J Korean Pediatr Soc.
2000 Mar;43(3):351-359.
Immune Response to SA14-14-2 Live Attenuated Japanese Encephalitis Vaccine
- Affiliations
-
- 1Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
- 2Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
- 3Division of Vectorborne Infectious Diseases, Center for Disease Control and Prevention, Ft. Collins, CO, USA.
Abstract
-
PURPOSE: SA14-14-2 live attenuated Japanese encephalitis (JE) vaccine has been administered safely and effectively to more than 100 million children in China since 1988, and recently licensure of the vaccine in Korea has been sought. Immune response to the vaccine was investigated.
MEHTODS: In the first clinical evaluation of the vaccine outside of China, we monitored side effects in 93 children and evaluated plaque reduction neutralizing test (PRNT) antibody and IgM antibody responses to a single dose given as primary JE vaccination in 74 children, 1-3 years old (mean age 27 months).
RESULTS
No significant adverse events were noted. PRNT antibodies (geometric mean titer [GMT] of 183) were produced in 96% of the 74 subjects. In 10 other children who previously had been immunized with two or three doses of inactivated JE vaccine, the booster administration of SA14-14-2 vaccine produced an anamnestic response in all, with a GMT of 3378. In a comparison group of 25 children previously immunized with two doses of inactivated vaccine, neutralizing antibody titers were detected in 16 (64%). Viral specific IgM was detected in nine primary vaccinees (13%) but in others, IgM may have declined to undetectable levels in the four week postimmunization sample.
CONCLUSION
Live attenuated SA14-14-2 JE vaccine is a promising alternative to the only commercially available live attenuated JE vaccine for national childhood immunization programs in Asia.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Japanese Encephalitis Vaccine: Worldwide and Korean Status
- Primary and Booster Immune Responses to Live Attenuated SA14-14-2 Japanease Encephalitis Vaccine in Korean Infants
- Investigation on the Frequency and Severity of Common Adverse Reactions of Japanese Encephalitis Vaccines
- The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
- Comparison of Four Serological Tests for Detecting Antibodies to Japanese Encephalitis Virus after Vaccination in Children
